Sphingosine-1-phosphate (S1P) is a biologically active sphingolipid metabolite that exerts important effects on numerous cellular events via cell surface receptors, S1P 1-5 . S1P influences differentiation, proliferation, and migration during vascular development. However, the effects of S1P signaling on early cardiac development are not well understood. To address this issue, we examined the expression of S1P regulatory enzymes and S1P receptors during cardiac development. We observed that enzymes that regulate S1P levels, sphingosine kinase and sphingosine-1-phosphate phosphatase, are expressed in the developing heart. In addition, RT-PCR revealed that four of the five known S1P receptors (S1P 1-4 ) are also expressed in the developing heart. Next, effects of altered S1P levels on whole embryo and atrioventricular (AV) canal cultures were investigated. We demonstrate that inactivation of the S1P producing enzyme, sphingosine kinase, leads to cell death in cardiac tissue which is rescued by exogenous S1P treatment. Other experiments reveal that increased S1P concentration prevents alterations in cell morphology that are required for cell migration. This effect results in reduced cell migration and inhibited mesenchymal cell formation in AV canal cushion tissue. These data indicate that S1P, locally maintained within a specific concentration range, is an important and necessary component of early heart development.
Introduction
Spingosine-1-phosphate (S1P) is a biologically active lysophospholipid that is involved in cellular differentiation, proliferation, migration, cytoskeletal reorganization, and apoptosis (Maceyka et al., 2002; Pyne and Pyne, 2000) . S1P action has been implicated in the regulation of numerous cardiovascular processes, including angiogenesis, vascular permeability, arteriogenesis, cardiac function, vascular development, and vascular tone control (Alewijnse et al., 2004; Allende and Proia, 2002; Levade et al., 2001) . S1P influences cellular events as an extracellular ligand that acts through the endothelial differentiation gene (EDG) family of receptors. S1P can also act as an intracellular second messenger that mobilizes intracellular stores of Ca 2+ and influences cell growth, independent of cell surface receptors (Meyer zu Heringdorf et al., 2003; Olivera et al., 2003; Pyne and Pyne, 2000) . Sphingosine kinase (SK) converts sphingosine to S1P in response to various stimuli (Maceyka et al., 2002; Pyne and Pyne, 2000) . Some of the factors that increase SK activity include vascular endothelial growth factor (VEGF), PDGF, TNFα, EGF, carbachol, and protein kinase C (Cuvillier et al., 1998; Pyne and Pyne, 2000) . In addition, transforming growth factor beta (TGFβ) up-regulates SK1 expression (Yamanaka et al., 2004) . S1P is important for cell survival as indicated by the fact that N,N-dimethylsphingosine (DMS) inhibits SK activity and induces cell death in rat neonatal cardiomyocytes (Karliner et al., 2001; Yatomi et al., 1996) . S1P can also protect cells from environmental stresses, as S1P reduced hypoxia induced cell death in rat neonatal cardiomyocytes (Karliner et al., 2001) .
The degradation and inactivation of S1P signaling involve cleavage into palmitaldehyde and phosphoethanolamine by S1P-lyase or dephosphorylation by sphingosine-1-phosphate phosphatase, SPP1 Pyne and Pyne, 2000) . SPP1 is expressed in the heart, liver, and kidney (Mandala et al., 2000) . Reduction of SPP1 activity with small inhibitory RNA (siRNA) in MCF7 cells reduces enzyme expression resulting in increased S1P levels within cells and increased S1P secretion . S1P signaling primarily flows from outside the cell to inside the cell through G-protein-coupled receptors on the cell surface. This family of five receptors are designated S1P [1] [2] [3] [4] [5] , formerly referred to as Edg1, Edg5, Edg3, Edg6, and Edg8 respectively Fukushima et al., 2001) . S1P 1-3 are widely expressed in embryonic and adult tissues, including the heart (Osborne and Stainier, 2003; Watterson et al., 2003) . In the cardiovascular system, S1P 1 is highly expressed in cardiomyocytes and vascular endothelial cells, while S1P 2 and S1P 3 are primarily expressed in vascular smooth muscle cells and cardiomyocytes (Alewijnse et al., 2004) . S1P 4 is primarily expressed in lymphoid tissue with some expression in spleen and lung but has not been previously reported in the heart (Graler et al., 1998; Watterson et al., 2003) . S1P 5 expression is generally restricted to brain and spleen but has also been detected in cardiomyocytes (Liliom et al., 2001; Watterson et al., 2003) . S1P receptors expressed in the cardiovascular system signal through a variety of pathways to both promote and inhibit cell migration. S1P 1 activation triggers Rac signaling, which stimulates endothelial cell migration . S1P 3 signals through G i , G q , and G 13 and can activate phospholipase C (PLC), inhibit adenylate cyclase, and promote endothelial cell migration Takuwa, 2002; Windh et al., 1999) . In contrast, S1P 2 activation inhibits cell migration in vascular smooth muscle cells, neutrophils, and B16 melanoma cells (Arikawa et al., 2003; Bornfeldt et al., 1995; Kawa et al., 1997) . S1P 2 activation inhibits Rac signaling and activates Rho signaling (Ishii et al., 2002; Takuwa, 2002) , which inhibits cell migration, in part through the induction of stress fibers (Takuwa, 2002) .
Initial evidence showing that S1P signaling influences heart development arose from identification of the miles apart (mil) mutation in zebrafish, a gene that encodes an S1P receptor most closely related to S1P 2 in mammals. The miles apart mutation impairs fusion of the bilateral heart tubes leading to cardia bifida (Kupperman et al., 2000) . Although cell migration of the precardiac cells is initially normal in the miles apart mutation, it was demonstrated that S1P receptor expression is required in extracardiac tissue for migration of the primitive heart tubes to the midline where they fuse to form the definitive heart tube (Kupperman et al., 2000) .
Although targeted deletion of S1P 2 or S1P 3 alone in mice had no adverse effects on embryogenesis, deletion of S1P 1 caused embryonic lethality between embryonic day (E) 12.5 and E14.5 (Ishii et al., 2002; Liu et al., 2000b; MacLennan et al., 2001) . Embryonic death results from a failure of the vascular smooth muscle cells (VSMC) to surround and support the developing vasculature leading to a massive hemorrhage (Liu et al., 2000b) . Additional experiments revealed that recruitment of the VSMC requires S1P 1 expression in the endothelial cells of the developing vessels (Allende et al., 2003) . Recently, S1P 1 , S1P 2 , and S1P 3 triple null embryos were generated, and they displayed a more severe phenotype that resulted in embryos dying earlier, between E10.5 and E11.5, than the knockout of S1P 1 alone (Kono et al., 2004) .
These reports indicate that S1P signaling is involved in early cardiac morphogenesis and maturation of the vascular system, but little is known about S1P signaling in cardiac tissue during early heart development. In particular, not much is known about the expression of S1P signaling components in the heart during embryogenesis, and there are no reports on what effects altered S1P levels have on cardiac development. This report begins to address these issues by demonstrating that enzymes and receptors involved in S1P signaling are expressed in the heart throughout early cardiogenesis. In addition, we illustrate that altered S1P signaling can disrupt normal heart development and, more specifically, cardiac cushion development.
Differentiation of the cardiac chambers is accompanied by septation of the heart, which involves formation of the cardiac cushions from E9.5 to 12.5. A key step in cardiac cushion development is transformation of endothelial cells into mesenchymal cells. These mesenchymal cells differentiate into fibroblasts and contribute to the formation of mature heart valves (Chin et al., 1992; Thompson and Fitzharris, 1979) . In both the atrioventricular (AV) canal and outflow tract regions of the heart, endothelial cells receive signals from the overlaying myocardium to transform and invade the underlying extracellular matrix (Runyan and Markwald, 1983) . Many signaling molecules, including TGFβ and VEGF, are involved in promoting and inhibiting endothelial to mesenchymal cell transformation (EMT) in the developing heart (Chang et al., 2004; Dor et al., 2001; Eisenberg and Markwald, 1995; Potts et al., 1991) . Disruption of normal cardiac cushion development leads to septation or valve defects, which are among the most common congenital heart malformations observed in humans (Hoffman, 1995a,b) .
This report demonstrates that elevated S1P levels inhibit cell migration and block endothelial to mesenchymal cell transformation in atrioventricular canals without inducing cell death. We also reveal that inhibition of S1P production, through treatment with dimethylsphingosine (DMS), leads to cell death in AV canal cells and loss of cardiomyocyte function. These data illustrate the need to carefully regulate the level of S1P during cardiac development, since S1P signaling influences cell migration, differentiation, and cell survival of embryonic cardiac cells.
Materials and methods

Chemicals
Sphingosine-1-phosphate (S1P; Sigma) was resuspended in 4% fatty acidfree bovine serum albumin (FAF-BSA; Sigma) to 5.25 mM by sonicating for 15 min at 4°C followed by incubation at 45°C for 1 h. N,N-dimethylsphingosine (DMS; Sigma, St. Louis, MO) was dissolved in 100% ethanol to a final concentration of 3.2 mM. SEW2871 (Ryan Scientific, Inc., Isle of Palms, South Carolina) was resuspended to 10 mM in dimethylsulfoxide (DMSO). Fumonisin B 1 (FB1; Sigma) was dissolved in water to a final concentration of 500 μM.
Reverse transcription (RT) and polymerase chain reaction (PCR)
Timed matings were used to obtain the appropriate stage embryos, with E0.5 being the day a vaginal plug was observed. For RT-PCR, total RNA was collected from whole mouse embryos or isolated hearts at E7.5 to E12.5 and from AV canals dissected from E9.5 hearts with the RNeasy kit (Qiagen, Valencia, CA). Embryonic and cardiac tissue was homogenized in 600 μl of lysis buffer by passing it through a 20-gauge needle 10 times, followed by total RNA isolation according to the animal tissue protocol provided with the RNeasy kit. Next, 1 μg total RNA was reverse transcribed with SuperScript III (Invitrogen, Carlsbad, CA) in a 20 μl reaction with Oligo-dT 12-18 primers according to manufacturer's recommendations. All PCR reactions contained 2× Master Mix (Promega, Madison, WI) with 100 ng of cDNA and 100 ng of each primer and were performed at an annealing temperature of 55°C for 35 cycles with the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA). All PCR primers were designed against mouse sequences and include glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control (forward 5′-TCAACGACCCCTTCATTGAC-3′, reverse 5′-ATGCAGGGAT-GATGTTCTGG-3′). Primers for sphingosine kinase 1, sphingosine kinase 2, and S1P phosphatase 1 were as reported (Pettus et al., 2003) . The primers for the S1P 1-4 receptor genes were as reported (Forrest et al., 2004) . S1P 5 primers were designed based on another report (Wang et al., 2002) . All of the primer pairs, except for SK1, were designed to flank an intron to prevent detection of genomic DNA. No DNA contamination was detected in any of the RT-PCR reactions, and the negative control PCR reactions (no template) for all of the primer pairs were negative (data not shown).
Whole embryo cultures (WEC)
C57BL/6 mice (Charles River Laboratories, Wilmington, MA) were used for all whole embryo and AV canal culture experiments. Following timed matings, E7.5 or E9.5 embryos were dissected from the uterine muscle in cold 1× Dulbecco's phosphate-buffered saline (D-PBS, Invitrogen). Embryos were transferred to fresh D-PBS to further dissect out the embryos and remove Reicherts's membrane while leaving the yolk sac intact. Embryos were transferred to 60-ml bottles (Wheaton, Millville, NJ) containing 5 ml 100% rat serum and cultured in a roller bottle system at 38°C for 24-48 h, as described (Sturm and Tam, 1993; Wei et al., 2001; Zhao and Rivkees, 2003) . Drugs (vehicle, 5 μM S1P, or 5 μM DMS) were added to the serum before the addition of 5-6 embryos per bottle.
Embryonic morphology was assessed following whole embryo cultures with a Zeiss Stemi 2000-C dissecting microscope. Digital images were captured for each embryo with an Olympus DP 10 camera.
Heart morphology was assessed by immunocytochemistry following WEC. Embryos were collected after 48 h of drug treatment and fixed in 4% paraformaldehyde (PFA, Sigma) overnight at 4°C. Following a wash in D-PBS, embryos were permeabilized with PBST (PBS with 0.5% Triton X-100) for 2 h followed by blocking with 2% BSA in PBST for 2 h both at room temperature. Embryos were incubated with a primary antibody to myosin heavy chain (MF20, Developmental Studies Hybridoma Bank, Iowa City, IA) overnight at 4°C, followed by a secondary antibody (GAM IgG conjugated to Alexa Fluor 488, Molecular Probes, Eugene, OR) incubation for 2 h at room temperature. Immunostaining was analyzed and documented with an Olympus Fluoview laser scanning confocal microscope.
E9.5 embryos treated for 24 h with vehicle, 5 μM S1P, or 5 μM DMS in the whole embryo culture system were used for histological examination of cardiac structures. Following fixation with 4% PFA, embryos were embedded in paraffin and sectioned with a Micron HM325 microtome (Walldorf, Germany). Slides containing 7 μM thick sections were deparaffinized and rehydrated through a series of ethanol/water washes. Sections were stained with Harris modified hematoxylin and eosin Y, both from Fisher Scientific (Fair Lawn, NJ) according to standard histological procedures.
Atrioventricular (AV) canal cultures
AV canal cultures were prepared from E9.5 mouse hearts, as described (Camenisch et al., 2002) . Briefly, embryos were isolated from the uterus in cold D-PBS, and AV canal regions were dissected away from the heart and sliced open using fine forceps. AV canals were stored in D-PBS on ice until all AV canals were isolated. They were then placed on collagen gels (1 mg/ml of rat tail type I collagen, Cohesion, Palo Alto, CA) in 4-well culture dishes (Nalge-Nunc, Naperville, IL). Three AV canal explants were placed endothelial side down on each collagen gel and incubated at 37°C in the presence of 5% CO 2 . After 2 h of incubation, vehicle, S1P, SEW 2871, FB1, or DMS was added directly to the explants to give final concentrations of drug in the gel cultures ranging from 0.1 μM to 5.0 μM. Cultures were treated again at 24 h and then allowed to grow further for a total of 48 h. The explants were assessed for cardiomyocyte contractions at 24 and 48 h to assess the health of the cultures. Photographs were taken of each explant at 48 h to assess the extent of outgrowth from the explant and the amount of EMT.
Live AV canal cultures were imaged with phase contrast methods on an Olympus IX70 inverted microscope. Digital photographs of the explants were taken with a color CCD camera (DEI-750-T, Image Processing Solutions, North Reading, MA). Photos were used to quantitate cellular outgrowth following drug treatment of cultures. The amount of cellular outgrowth away from the muscle explant was calculated with the help of the Image-Pro Plus software (Media Cybernetics, Silver Springs, MD). The extent of outgrowth was outlined manually for each explant, the measurement was taken twice, and the average was used to calculate the total area of the explant and surrounding cellular outgrowth. Next, the muscle explant area was calculated and subtracted from the total area to give the final area of cellular outgrowth. The outgrowth area for each drug treatment or vehicle control was determined by averaging several explants over multiple experiments, with the P value determined by a Student's t test provided with the Microsoft Excel program. Outgrowth area is presented as a percent of vehicle control, specific for each drug treatment, and the error bar is a measure of the standard error of the mean.
Cell viability assays were performed on AV canal cultures grown for 48 h. The LIVE/DEAD Viability/Cytotoxicity kit (Molecular probes) was used according to manufacture's recommendations to asses cell viability. Briefly, cultures were rinsed two times with 1× D-PBS and then incubated with 2 μM calcein AM and 4 μM ethidium homodimer-1 (EthD-1) in D-PBS for 30 min at room temperature. Cultures were examined and photographed with an Olympus Fluoview laser scanning confocal microscope.
The level of apoptosis in AV canal cultures was assessed after drug treatment with the In Situ Cell Death Detection kit (Roche, Mannheim, Germany) according to the manufacturer's instructions, as reported (Wendler et al., 2003; Zhao and Rivkees, 2003) . Briefly, AV canal cultures were fixed overnight with 4% PFA at 4°C, followed by permeabilization with 0.3% Triton X-100 for 20 min at room temperature. Cultures were incubated with the TUNEL enzyme for 1 h at 37°C and counterstained with propidium iodide. TUNEL staining was assessed and documented with an Olympus Fluoview laser scanning confocal microscope.
The actin cytoskeleton of AV canal cells were visualized with phalloidin conjugated to Alexa Fluor 488 (Molecular Probes) and counterstained with an antibody to myosin heavy chain to identify cardiomyocytes. AV canals were cultured for 48 h then fixed in 4% paraformaldehyde for 2 h at room temperature. Next, cultures were blocked with 2% goat serum/2% bovine serum albumin in PBS for 2 h at room temperature. Primary antibody, MF20, was diluted 1/20 in blocking solution and incubated on the cultures overnight at 4°C. Next, cultures were incubated with the secondary antibody goat anti-mouse IgG conjugated to Alexa Fluor 546 (Molecular Probes) at 1/200 dilution and phalloidin-Alexa 488 at 1/50 dilution in blocking buffer for 3 h at room temperature. Collagen cultures were mounted on microscope slides with Fluoromount-G (Electron Microscopy Sciences, Hatfield, PA), and images were taken with an Olympus Fluoview laser scanning confocal microscope.
Results
Enzymes and receptors responsible for S1P signaling are expressed in developing embryonic and cardiac tissue Two sphingosine kinase enzymes (SK1 and SK2) and two sphingosine-1-phosphate phosphatase enzymes (SPP1 and SPP2) are present in mammalian adult and embryonic tissues (Argraves et al., 2004; Johnson et al., 2003; Liu et al., 2000a; Mandala et al., 2000) . These enzymes are responsible for regulating the local concentration of S1P (Pyne et al., 2004; Watterson et al., 2003) . Reverse transcriptase PCR was used to assess the expression of genes encoding these enzymes in whole mouse embryos and cardiac tissue at early developmental stages.
SK1, SK2, and SPP1 mRNA expression was detected as early as E7.5 in whole mouse embryos and throughout early embryonic development up until E12.5, older embryos were not examined (Fig. 1A) . Expression of SK1, SK2, and SPP1 mRNA was also observed in isolated cardiac tissue beginning at E8.5 and throughout cardiogenesis up to E12.5 (Fig. 1A) . Expression of the S1P enzymes' mRNA was detected in AV canals isolated from E9.5 hearts (Fig. 1A) , and their expression was also observed after E9.5 AV canals were cultured on collagen gels for 48 h (data not shown).
An important part of S1P action involves signaling through cell surface receptors (Anliker and Chun, 2004) . To determine which of the known S1P receptors are expressed during cardiac development, RT-PCR was performed on whole embryo and isolated heart RNA. We detected S1P 1-4 but not S1P 5 expression in heart tissue from E8.5 to E12.5 (Fig. 1A) . S1P 1-4 receptors were also detected in isolated AV canals from E9.5 hearts before and after 48 h in culture on collagen gels (Fig. 1A and data not shown). S1P 1-4 but not S1P 5 expression was detected by RT-PCR in embryos without hearts from E7.5 to E12.5 (Fig. 1A) . Effectiveness of the S1P 5 primers was confirmed by RT-PCR preformed on RNA isolated from neonatal oligodendrocytes (Fig. 1B) .
Alteration in S1P signaling disrupts embryonic development
After demonstrating that components of S1P regulation and signaling were present in the heart during early embryonic development, whole mouse embryo cultures were used to explore the role of S1P signaling during cardiogenesis. The advantage of whole embryo cultures is the ability to add reagents directly to the developing embryos and determine their effect on embryogenesis independent of maternal factors. We examined the effects of elevated S1P levels through addition of exogenous S1P and the effects of decreased S1P production with DMS treatment.
A range of S1P concentrations (1 μM to 10 μM) were tested based on reported doses used for treating cells in culture (Robert et al., 2001; Sanna et al., 2004) . It was observed that 5 μM S1P was the lowest dose that gave a consistent phenotype. Fig. 1 . Genes involved in S1P signaling are expressed in murine embryos and hearts throughout embryogenesis. (A) Reverse transcriptase-PCR was performed on total RNA isolated from whole embryos (E7.5), whole embryos without hearts (E8.5-E12.5), whole hearts (E8.5-E12.5), and AV canal regions of E9.5 hearts. All PCR reactions were done with an equivalent amount of cDNA following RT reactions with 1 μg total RNA. Negative controls for all the primers confirmed no genomic DNA contamination (data not shown). (B) Total RNA was isolated from neonatal oligodendrocytes and used for RT-PCR under the same conditions described for embryo and heart RNA. S1P 5 primers produced a single product of the predicted size, thus confirming their effectiveness. L, 1KB DNA ladder (Gibco); GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SK1, sphingosine kinase 1; SK2, sphingosine kinase 2; SPP1, sphingosine-1-phosphate phosphatase 1; S1P 1-5 , sphingosine-1-phosphate receptors 1-5.
Addition of exogenous S1P (5 μM final concentration) to whole embryos at E7.5 consistently resulted in smaller embryos with disrupted morphology, including abnormal heart formation (Fig. 2) . Elevated S1P levels also disrupted cardiac development when older embryos were cultured. Treatment of E9.5 embryos with 5 μM S1P for 24 h caused dilation of the primitive ventricle and reduced cellularity in AV canal cushions (Fig. 3) . S1P-treated embryos had heart rates consistent with control embryos treated with vehicle (data not shown).
Next, we examined effects of blocking S1P production. A range of DMS doses (1 μM to 10 μM) was evaluated with the whole embryo culture system based on reported effectiveness of DMS on cultured cells (Karliner et al., 2001) . It was observed that 5 μM DMS gave the most consistent phenotype in whole embryo cultures without killing the embryo. DMS-treated E7.5 embryos were much smaller and had reduced cellularity in cardiac tissue, as seen by a reduction in myosin heavy chain and propidium iodide staining compared to vehicle treated embryos (Fig. 2) . DMS treatment of E9.5 embryos also affected cardiac development including reduced cellular invasion of AV canal cushions (Fig. 3) .
Elevated heart rates were observed for E7.5 DMS-treated embryos, a sign that the hearts could be undergoing cardiac failure (data not shown). Altered S1P signaling had no direct effect on heart rate, based on the addition of either S1P or DMS to isolated E12.5-13.5 hearts (vehicle, N = 6; 5 μM S1P, N = 6; 5 μM DMS, N = 6). Heart rates were measured at 5, 15, and 60 min after treatment.
Elevated S1P concentration inhibits cell migration and blocks endothelial to mesenchymal cell transformation (EMT) in AV canal cultures Whole embryo cultures revealed that elevated S1P levels affected AV canal development by reducing the number of cells in the cardiac cushions. A similar effect on cushion development was reported with elevated levels of VEGF, which like S1P is a potent angiogenic factor (Dor et al., 2001) . In order to investigate the mechanism of S1P action on cardiac cushion development, isolated AV canals were cultured on Type I collagen gels. This system has been used extensively to examine signaling pathways involved in endothelial to mesenchymal cell transformation in cardiac cushion tissue. In this report, AV canal cultures were used to assess the effect of altered S1P signaling on the health of AV canal tissue which consists of three cell types, endothelial cells, mesenchymal cells, and cardiomyocytes. These cultures were also used to monitor cell migration onto the surface of the gels as well as formation of mesenchymal cells that invade the collagen matrix.
To assess elevated S1P levels on AV canals, explants were incubated with a range of S1P doses (from 0.1 to 2.5 μM final concentration). The health of S1P-treated AV canals was monitored by several methods. First, we determined whether explants were beating after 24 and 48 h in culture as an indicator of explant health, specifically cardiomyocyte health. Vehicle control and 0.1 μM S1P-treated cultures both had 100% of their explants beating at 24 and 48 h (Table 1, data not shown). At the highest concentration of S1P (2.5 μM), 96% of the explants were still beating after 48 h in culture (Table 1) . Fig. 2 . Altered S1P signaling disrupts embryogenesis in vitro. Whole embryos were cultured for 48 h as described and treated with (A, D) vehicle only, (B) 5 μM S1P, or (C, E) 5 μM DMS. MF20, an anti-myosin heavy chain antibody, was used to highlight cardiac tissue (green stain) in these embryos. Embryos were counterstained with propidium iodide (red stain) which labels all nuclei. S1P treatment disrupted embryonic and cardiac morphology (B). Disruption of S1P production also altered embryonic and cardiac development (C) compared to vehicle control (A). Higher magnification of a DMS-treated embryo shows reduced cellularity and reduced myosin heavy chain expression in the heart (E) compared to vehicle control (D). Images are stacked confocal pictures of a Z-series taken through each of the embryos. Scale bar equals 100 μM. H, head; V, ventricle; T, tail.
Whole embryo cultures indicated that S1P was altering cardiac development without causing cell death. To confirm this observation, AV canal cultures were stained with the LIVE/ DEAD Viability/Cytotoxicity kit. After culturing AV canals for 48 h with 2.5 μM S1P or vehicle control, live cultures were treated with the LIVE/DEAD assay and examined with a scanning laser confocal microscope. This kit stains live cells with calcein AM, which fluoresces green when excited, and dead cells with ethidium homodimer-1, which fluoresces red. This viability assay revealed that S1P treatment of AV canals did not increase cell death, in either cells on the collagen gel surface or endothelial cells or cardiomyocytes within the explanted heart tissue, compared to the vehicle control (Fig.  4) . Cell death was examined further with TUNEL analysis. This also demonstrated that S1P treatment does not significantly increase apoptosis in AV canal cultures (data not shown).
Next, cell migration and EMT were examined in S1P-treated AV canal cultures. The lowest concentration of S1P (0.1 μM) tested had no effect on either cellular outgrowth or mesenchyme formation in AV canal cultures (data not shown). Addition of 0.5 μM of S1P to AV canal cultures reduced cell outgrowth away from the muscle explants by 39%, as compared with vehicle (Fig. 5) . The morphology of the migratory cells on the surface of the collagen did not appear altered, but there was a 39% reduction in the number of explants with at least 3 mesenchymal cells invaded into the collagen gel after 48 h (Figs. 6) . The average number of mesenchymal cells that invaded into the collagen gel in control explants was 33.75 ± 4 (N = 20). So explants identified as inhibited (fewer then 3 mesenchymal cells) have at least a 95% reduction in the number of transformed cells invading the collagen gel. At 1.0 μM of exogenous S1P treatment, cellular outgrowth away from AV canal explants was inhibited 61%. Not only were cells unable to migrate away from the explants, treatment was also associated with fewer cells on the surface of the gel. Cells on the surface of the gel had fewer cellular processes extending away from their cell bodies, and many were completely round (Fig. 5 ). In addition, mesenchymal cell formation was inhibited by 62% with moderate S1P (1.0 μM) treatment (Fig. 6) .
2.5 μM S1P treatment severely inhibited outgrowth from AV canal explants, with a reduction of greater than 75% compared to vehicle controls (Fig. 5) . S1P completely blocked EMT (Fig.  6) , none of the explants treated with 2.5 μM S1P were able to produce more than 2 mesenchymal cells, compare Fig. 5B with C. Most of the cells on the collagen gel surface failed to extend filapodia and were rounding up (Figs. 5E, F) . Analysis of cell shape revealed an altered cytoskeletal structure in S1P-treated cells. We observed that cells treated with S1P formed stress fibers around the inside of the cell, as highlighted by phalloidin-Alexa Fluor488 staining (Fig. 7) . Upon treatment with 2.5 μM S1P, cells were unable to from filapodia or lamellipodia and some round up on the surface of the gel (Fig. 7) . Control cultures display cells on the gel surface with multiple cellular processes that are highly branched, indicating that these cells are actively migrating on the collagen matrix (Fig. 7) . In contrast to controls, S1P-treated cells on the surface of the collagen gel present very few cellular extensions, if any, and those that have small extensions are not branched at all (Fig. 7) . Counterstaining explants with MF20, an antibody to myosin heavy chain, demonstrate that cardiomyocytes stay primarily within the explanted tissue and are not the cells showing altered morphology on the collagen gel surface in response to S1P treatment (Fig. 7) . Elevated S1P appears to prevent these cells from adopting a fibroblastic phenotype, characteristic of migratory cells, leaving them with a more endothelial phenotype.
S1P is required for cell survival in AV canal tissue
Inhibition of S1P production in whole embryo cultures, with DMS treatment, caused a loss in cellularity in the heart and cardiac cushions. To assess this observation in more detail, AV canal cultures were treated with a range of DMS concentrations (0.5 μM to 2.5 μM). Cultures were then examined for cell death, cell migration, and mesenchyme formation. DMS treatment of 0.5 and 1.0 μM had no effect on cardiomyocyte viability, as 100% of the explants at these concentrations were beating after 24 and 48 h in culture. A DMS concentration of 0.5 μM had no effect on either cellular outgrowth or endothelial to mesenchymal cell transformation in AV canal cultures (Figs. 6, 8B, G) . However, 1.0 μM DMS inhibited cellular outgrowth by 33% and blocked mesenchymal formation by 37% (Figs. 6, 8C, G) .
The most prominent effects of DMS were observed when AV canal explants were treated with 2.5 μM DMS. After 24 h of 2.5 μM DMS treatment, 68% of the explants were beating, and after 48 h, only 27% were still beating compared with 100% of the controls and 96% of S1P-treated explants (Table 1) . TUNEL analysis performed on 2.5 μM DMStreated explants revealed that nearly all of the cells on the collagen gel surface were positive for apoptosis as well as many of the cells in the muscle explant (Fig. 9 ). This treatment also caused a near complete block in cellular outgrowth from the explants, and EMT was inhibited 100% (Figs. 6, 8E, G) . The only cells on the surface of the gel around the muscle explant were dead and rounded up (Figs. 7,  9 ). Analysis of DMS (2.5 μM)-treated explants with the LIVE/ DEAD kit indicated that most of the cells in and around the muscle explant were dead (Fig. 4) .
The specificity of the DMS treatment was confirmed by the addition of S1P (0.5 μM)-to DMS (2.5 μM)-treated explants. S1P increased the outgrowth of cells away from AV canal explants from 17% to 71% of controls and increased mesenchyme formation in cultures treated with DMS (Figs.  6, 8F, G) . Cardiomyocyte viability was also improved with S1P treatment. After 48 h, S1P increased the proportion of beating explants from 27% to 78% (Table 1) . These experiments show that S1P is required to maintain healthy AV canal cultures with beating cardiomyocytes and transformed mesenchymal cells. S1P inhibition of cell migration and EMT is not mediated by S1P 1 or through conversion to ceramide Treatment with SEW 2871, an S1P 1 specific agonist, had no effect on AV canal cultures. Both cell migration away from explants and mesenchyme formation were comparable to vehicle controls (Figs. 6, 10 ). Examination of cell morphology, with phalloidin staining, was also comparable to vehicle treated cultures (data not shown). In addition, SEW 2871 was unable to rescue cellular outgrowth (Fig. 10) or mesenchymal cell formation (data not shown) in DMS-treated AV canal cultures. Although S1P 1 is expressed in early stage AV canals, its activation alone failed to recapitulate the effects of S1P.
Sphingosine-1-phosphate can be converted into ceramide, a potent promoter of apoptosis, by first being converted to sphingosine. Sphingosine is then converted into ceramide by ceramide synthase (Spiegel and Kolesnick, 2002) . To test if the effects of elevated S1P were due to a conversion of S1P into ceramide, AV canal cultures were treated with fumonisin B 1 (FB1) which blocks ceramide synthase activity (Le Stunff et al., 2002) . Treatment of AV canal explants with FB1 (5 μM final concentration) alone had no effect on AV canal outgrowth (Fig. 11) and only a slight inhibition on mesenchymal cell formation (data not shown). Treatment of AV canals with FB1 in the presence of 2.5 μM S1P was Fig. 4 . Decreased S1P production but not elevated S1P levels leads to cell death in AV canal tissue. AV canal explant health was assessed at the end of 48 h in culture with the LIVE/DEAD Viability/Cytotoxicity kit (Molecular Probes). Cultures treated with either control vehicle (A, D), 2.5 μM S1P (B, E), or 2.5 μM DMS (C, F) were examined for live (green) or dead (red) cells with confocal scanning laser microscopy. Control and S1P-treated explants both contained a few dead cells around the periphery of the explants, but the majority of cells within the explant and on the gel surface were alive. In contrast, DMS treatment caused most of the cells with in the explant to die as indicated by the large number of red cells. Scale bar equals 100 μM.
unable to rescue either cell outgrowth or mesenchymal cell formation (Fig. 11) . These data indicate that S1P signaling involves direct effects on AV canal development, rather than through a conversion to ceramide.
Discussion
Sphingosine-1-phosphate is a signaling molecule that affects many different cellular processes, including cell proliferation and cell migration, in a variety of cardiovascular cell types including vascular smooth muscle cells, cardiomyocytes, and endothelial cells (Takuwa, 2002) . Much effort has focused on the role of S1P signaling during the development of the vascular system and on the function of vascular tissue, but relatively little is known about S1P signaling during heart development. This report demonstrates that S1P signaling is important for cardiac development, and that alterations in S1P level can lead to cardiac malformations or cell death. This is the first evidence indicating that S1P signaling in cardiac tissue is important for heart development.
Local production of S1P by sphingosine kinase 1 and 2 (SK1, SK2) is reported in adult mammalian hearts and in whole mouse embryos as early as E7.5 (Argraves et al., 2004; Liu et al., 2000a) . Using RT-PCR analysis, we extend this analysis by documenting SK1 and SK2 expression in cardiac tissue as early as the linear heart tube stage (E8.5) and continuing through formation of the four-chamber heart at E12.5, the latest stage examined (Fig. 1) . One method to inactivate S1P signaling is conversion to sphingosine by S1P phosphatase (Pyne et al., 2004) . Both mouse and human S1P phosphatase 1 (SPP1) have been characterized and are expressed in adult heart tissue Mandala et al., 2000) . Our findings show SPP1 expression in the heart as early as E8.5 and throughout the early stages of cardiac development (E8.5-E12.5; Fig. 1 ). The expression data for SK and SPP1 support the idea that S1P Fig. 5 . S1P inhibits cellular outgrowth from AV canal cultures. AV canals isolated from E9.5 hearts were cultured on collagen gels for 2 h and then treated with vehicle control (4% FAF-BSA, A, B), 0.5 μM S1P, 1.0 μM S1P (C, D), or 2.5 μM S1P (E, F). Following 48 h of total incubation, phase contrast images were taken at low magnification to show extent of endothelial and mesenchymal cell outgrowth away from the muscle explant (A, C, E). Increasing concentrations of S1P caused a decrease in cellular outgrowth (G). High magnification shows cell morphology (B, D, F), with high levels of S1P treatment (1.0 and 2.5 μM) causing cells to round up (D, F). The total area of outgrowth was determined for each explant by outlining the extent of outgrowth and subtracting from that the area of the explant, demonstrated in panel A. The average outgrowth for each treatment was calculated and displayed as a percent of vehicle control (G) . N, number of explants measured for each treatment; M, muscle explant. Scale bar equals 100 μM. Arrow points to mesenchymal cell. *P ≤ 0.008, **P ≤ 1 × 10 −9 . Fig. 6 . Altered S1P signaling inhibits endothelial to mesenchymal cell transformation (EMT) in AV canal cultures. After 48 h of drug treatment, the amount of EMT in E9.5 AV canal cultures was determined. Using a phase contrast microscope, live cultures were scored for the presence of transformed mesenchymal cells that had invaded the collagen gel matrix. Explants were scored as inhibited if 0-2 mesenchymal cells were found in the gel surrounding the explant. Results are displayed as the percent of explants with impaired EMT. Increasing S1P concentrations progressively inhibit mesenchymal cell formation in the AV canal cultures, and the highest concentration of S1P (2.5 μM) completely blocks EMT. The highest level of DMS (2.5 μM) also completely blocks EMT. However, a low amount of S1P (0.5 μM) rescues EMT in DMS (2.5 μM) treated cultures. In addition, this graph reveals that 2.5 μM SEW 2871, an S1P 1 agonist, has no affect on EMT in these cultures. N equals the number of explants examined for each drug treatment.
levels are locally regulated in cardiac tissue during early heart development. Two other pieces of data described in this report support the idea that regulation of S1P, specifically, is critical for cardiac cushion development. First, fumonisin B 1 was not able to rescue S1P-treated AV canal cultures (Fig. 11) , indicating that effects of increased S1P are not caused by a conversion into ceramide. Second, DMS-treated cultures were rescued by exogenous S1P, indicating that DMS-induced cell death was caused by a reduction in S1P levels (Fig. 8) .
Although S1P can act as a 2 nd messenger inside the cell, the majority of S1P influences on cell signaling are attributed to binding cell surface receptors (Anliker and Chun, 2004; Payne et al., 2002; Watterson et al., 2003) . S1P receptor expression has recently been reported in the developing murine embryo, allantois, and yolk sac (Argraves et al., 2004) . We observed four S1P receptors (S1P 1-4 ) expressed in the developing embryo from E7.5 through E12.5, and the same receptors were detected in the developing heart from E8.5 to E12.5 (Fig. 1) . A new finding was that S1P 4 , which is almost exclusively expressed in the lymphoid tissue (Graler et al., 1998) , was detected in embryonic cardiac tissue (Fig. 1) .
Whole embryo cultures revealed a link between S1P signaling and cardiac cushion formation since both an increase and a decrease in S1P reduced the number of cells within the AV canal cushions (Fig. 3) . These results begin to indicate that maintaining the local S1P concentration within a narrow range is critical for proper cardiac development. Experiments with isolated AV canals in culture confirm the sensitivity of this tissue to changes in S1P concentration and suggest that different mechanisms are responsible for disrupted cushion development depending on whether S1P levels go up or down. The in vitro cultures indicate that elevated S1P prevents cell migration (Fig.  5) and that decreased S1P causes cell death (Fig. 9) , and that Fig. 7 . S1P treatment prevents cell shape changes required for mesenchymal cell formation. AV canal cultures from E9.5 hearts were cultured on collagen gels for 48 h with vehicle control (4% FAF-BSA, A-D), 2.5 μM S1P (E-H), or 2.5 μM DMS (I-L). The actin cytoskeleton of AV canal cells was detected with phalloidin conjugated to Alexa Fluor488. Phalloidin labels all cells in the AV canal cultures including cells in the explant and cells that have migrated away from the explant (A, E, I). MF20, a muscle-specific antibody to myosin heavy chain, identified cardiomyocyte cells within the AV canal explants (B, F, J). An overlay of the phalloidin and myosin staining demonstrates that cardiomyocytes do not migrate away from the explants (C, G, K). A closer examination at higher magnification reveals the morphology of cells on the collagen gel surrounding the muscle explants (D, H, L) . Vehicle-treated cultures have numerous mesenchymal cells, each with many filapodia, migrating away from the explant (D). In contrast, cells in S1P-treated cultures have few cellular processes, and they retain cell to cell contacts characteristic of an endothelial phenotype (H). DMS treatment causes cells on the gel surface to round up (L). Scale bar equals 100 μM, except panels D, H, L where the scale bar is 50 μM.
both mechanisms prevent cells from colonizing the cardiac cushions.
The transformation of endothelial cells into mesenchymal cells that then invade the cardiac cushions is critical for proper valve formation (Chin et al., 1992; Thompson and Fitzharris, 1979) . Unlike chicken AV canal explants, which have sheets of endothelial cells spreading out from the muscle explant, mouse AV canal explants have fewer endothelial cells spread on the gel surface (Fig. 5) . The vast majority of cells that migrate away from mouse AV canal explants have a cell shape characterized by many cellular processes (lamellipodia and filapodia) extending out from the cell body. Control explants have many of these fibroblastic type cells migrating away form the muscle explant, some on the surface of the gel and some that invade the collagen gel (Fig. 7) . Like chicken cultures, the cells that invade the collagen gel are identified as mesenchymal cells (Fig. 5) .
Increasing S1P concentrations in AV canal cultures progressively inhibited cellular outgrowth away from the muscle Fig. 8 . Sphingosine kinase activity is required for cellular outgrowth in AV canal cultures. AV canals isolated from E9.5 hearts were cultured on collagen gels and treated with vehicle control (0.08% ETOH in 4% FAF-BSA, A), 0.5 μM DMS (B), 1.0 μM DMS (C, D), 2.5 μM DMS (E), 2.5 μM DMS + 0.5 μM S1P (F). Following 48 h of incubation, phase contrast images of live cultures were taken at low magnification (A, B, C, E, F) to show the extent of endothelial and mesenchymal outgrowth from the muscle explant. DMS treatment of 1.0 and 2.5 μM inhibited outgrowth (C, E), which was rescued with addition of exogenous S1P (F). High magnification shows rounded cell morphology in 1.0 μM (D) and 2.5 μM (data not shown) DMS-treated cultures. All scale bars are 100 μM. The average areas of outgrowth from AV canals were calculated for each treatment group and represented as a percent of vehicle control (G) . N, number of explants measured for each treatment. Scale bar equals 100 μM. *P ≤ 0.01, **P ≤ 1 × 10 −14 , ***P ≤ 1 × 10 −8 . explants, and this directly correlated with a decrease in the number of explants with transformed mesenchyme (Figs. 5, 6 ). At low levels of S1P concentration (0.5 μM), cellular outgrowth was 61% of controls, and the amount of EMT was 63% of controls. At 1.0 μM S1P, cell outgrowth is reduced to 38% of control, and EMT is like wise reduced to 38% of controls (Figs. 5, 6) . Finally, at higher concentrations of S1P (2.5 μM), outgrowth is only 23% of controls, and EMT has been completely blocked (Figs. 5, 6 ). This increasing inhibition in cell migration is associated with changes in morphology of cells on the surface of the collagen gels (Fig. 7) . S1P treatment prevents cells from forming migratory cells with many filapodia. Instead, S1P causes cells on the surface of the gel to maintain an endothelial phenotype with few cellular processes and more cell-cell contacts (Fig. 7) . These findings suggest that reduced EMT in S1P-treated cultures is due to an inhibition of cell migration. Although in many systems S1P promotes cell migration Wang et al., 1999) , there is evidence that S1P can trigger a rearrangement of the cytoskeleton that leads to an inhibition of cell migration (Okamoto et al., 2000; Olivera et al., 2003) . Over-expression of SK1 in NIH 3T3 cells induced stress fibers and inhibited cell migration, and this effect was mediated by G 12/13 and Rho signaling (Olivera et al., 2003) . S1P causes cell rounding in HEK 293 and CHO cells which was mediated by the S1P 2 and S1P 4 respectively, and S1P induced peripheral stress fibers similar to those seen in S1P-treated AV canal cultures (Graler et al., 2003; Van Brocklyn et al., 1999) . S1P can also inhibit cell migration in tumor cells (Lepley et al., 2005) . This effect is mediated through S1P 2 and the Rho/Rho kinase pathway and leads to changes in the actin cytoskeleton (Lepley et al., 2005) .
A cell's migratory response to S1P stimulation is dependent on which S1P receptor(s) are activated (Takuwa, 2002) . Activation of S1P 1 or S1P 3 promotes cell migration of endothelial cells and of CHO cells over-expressing these receptors (Kon et al., 1999; Lee et al., 1999; Okamoto et al., 2000) . In contrast, the S1P 2 receptor blocks cell migration in several cell types including neutrophils, B16 melanoma cells, vascular smooth muscle cells, and CHO cells over-expressing S1P 2 (Bornfeldt et al., 1995; Kawa et al., 1997; Okamoto et al., 2000; Sadahira et al., 1992) . Since S1P 1 is known to promote cell migration, it is unlikely that this receptor is mediating the S1P response seen in cardiac cushions. This idea was strengthened when no effects on cell migration or transformation were observed with SEW 2871, an S1P 1 -specific agonist, treatment of AV canal cultures (Fig. 10 ). In addition, SEW 2871 was unable to rescue cell migration, EMT or even cell survival in DMS-treated cultures (Fig. 10) . These data indicate that G i protein, the only G protein that S1P 1 signals through, is not involved in the disruption of cardiac cushion development caused by elevated S1P levels. S1P 2 is a possible candidate as the mediator of S1P signaling in AV canals, since it inhibits cell migration and causes cell Fig. 10 . S1P 1 agonist (SEW 2871) has no effect on AV canals. (A) Phase contrast image of normal outgrowth from an AV canal culture after 48 h of exposure to SEW 2871, an S1P 1 -specific agonist. Quantitation of endothelial cell outgrowth from SEW 2871-treated AV canal muscle explants (M) demonstrated no difference from vehicle treated explants (C). Unlike S1P, SEW 2871 is unable to rescue DMS-induced outgrowth inhibition (B, C). Final concentrations for all drugs were 2.5 μM. The number of explants (N) measured for each treatment: vehicle, N = 13; SEW 2871, N = 13; DMS, N = 20; SEW 2871 + DMS, N = 4. Scale bar equals 100 μM. Fig. 11 . S1P inhibition of outgrowth is not through conversion to ceramide. (A) Phase contrast image revealing normal cellular outgrowth from an AV canal explant treated with 5 μM fumonisin B1 (FB1), an inhibitor of ceramide synthase. FB1 blocks the conversion of sphingosine into ceramide and is unable to rescue mesenchymal cell outgrowth in S1P-treated explants (B, C) . N, number of explants measured for each treatment. Scale bar equals 100 μM. *P ≤ 1 × 10 −8 .
rounding in these cultures. These same effects are observed with S1P treatment in other systems (Osada et al., 2002; Van Brocklyn et al., 1999) . S1P 2 can signal through G i , but it would likely signal through one or both of the other G proteins (G 12/13 , G q ) that it interacts with (Anliker and Chun, 2004) , in order to inhibit cell migration in cushion tissue. Two other S1P receptors (S1P 3 and S1P 4 ) expressed in AV canal tissue cannot be ruled out as mediators of S1P signaling either because they also signal through G proteins other than G i . S1P 3 interacts with G 12/13 and G q and S1P 4 signals through G 12/13 (Anliker and Chun, 2004; Graler et al., 2003) . Although we speculate that S1P 2 is the mediator of S1P signaling in cardiac cushions, gene knockout experiments show that S1P 2 is not required for normal development (Kono et al., 2004) . This contradiction may be explained by a redundancy in function of known cardiac S1P receptors or by as yet unidentified S1P receptor(s). Alternatively, S1P effects on cultured AV canals may be caused by the activation of multiple S1P receptors. S1P acting as a second messenger inside the cell could be another pathway, since reports demonstrate that S1P can be transported into the cell through the cystic fibrosis transmembrane regulator (Boujaoude et al., 2001; Meyer zu Heringdorf et al., 2001) .
Experiments have demonstrated that VEGF signaling is critical for preventing EMT in areas outside the cardiac cushion and within the cardiac cushion later in development to bring cell transformation to an end (Chang et al., 2004; Dor et al., 2001) . A reduction in VEGF also inhibits AV canal EMT (Enciso et al., 2003) . In addition, VEGF activates sphingosine kinase and increase S1P levels in human umbilical vein endothelial cells (Shu et al., 2002) . These observations along with the data presented in this report raise the possibility that S1P mediates the effects of VEGF on cardiac cushions during heart development. Another possibility is that factors that are highly angiogenic, like S1P and VEGF, maintain endothelial cells in a proliferative state that is resistant to cell transformation signals. This could also explain why the complete lose of these factors is also detrimental to endothelial cells and the formation of mesenchymal cells.
This report provides evidence that elevated S1P is acting to prevent the formation and migration of mesenchymal cells. What is not yet clear is whether S1P acts directly on endothelial cells or indirectly through alterations in cardiomyocyte signaling. Overall, our findings indicate that careful regulation of S1P signaling is important for cardiac viability and morphogenesis. Further analysis of factors that regulate S1P levels in cardiac tissue will be an important step in describing the role of S1P during normal heart development.
